RU2015113959A - Индолины - Google Patents

Индолины Download PDF

Info

Publication number
RU2015113959A
RU2015113959A RU2015113959A RU2015113959A RU2015113959A RU 2015113959 A RU2015113959 A RU 2015113959A RU 2015113959 A RU2015113959 A RU 2015113959A RU 2015113959 A RU2015113959 A RU 2015113959A RU 2015113959 A RU2015113959 A RU 2015113959A
Authority
RU
Russia
Prior art keywords
compound
pharmaceutically acceptable
alkyl
acceptable salt
aryl
Prior art date
Application number
RU2015113959A
Other languages
English (en)
Russian (ru)
Inventor
Джоан Хизер Хогг
Стейси Ремисзевски
Вэйя ЮНЬ
Original Assignee
Ф. Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг
Publication of RU2015113959A publication Critical patent/RU2015113959A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
  • Epidemiology (AREA)
RU2015113959A 2012-10-11 2013-10-01 Индолины RU2015113959A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261712317P 2012-10-11 2012-10-11
US61/712,317 2012-10-11
PCT/EP2013/070407 WO2014056755A1 (en) 2012-10-11 2013-10-01 Indolines

Publications (1)

Publication Number Publication Date
RU2015113959A true RU2015113959A (ru) 2016-12-10

Family

ID=49293651

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015113959A RU2015113959A (ru) 2012-10-11 2013-10-01 Индолины

Country Status (10)

Country Link
US (1) US9403768B2 (enExample)
EP (1) EP2906535B1 (enExample)
JP (1) JP6333825B2 (enExample)
KR (1) KR20150065718A (enExample)
CN (1) CN104736519B (enExample)
CA (1) CA2884708A1 (enExample)
HK (1) HK1211025A1 (enExample)
MX (1) MX2015004465A (enExample)
RU (1) RU2015113959A (enExample)
WO (1) WO2014056755A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170062481A (ko) 2014-09-29 2017-06-07 뉴욕 인스티튜트 오브 테크놀로지 히스 전기도 교대맥을 기록하고 다양한 조건에 적용하는데 사용하기 위한 카테터
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
CA3148504A1 (en) 2019-08-08 2021-02-11 Institute For Cancer Research D/B/A/ The Research Institute Of Fox Chase Cancer Center Combination therapy for treatment of cancer
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2733995B1 (fr) 1995-05-09 1997-07-25 Inst Nat Sante Rech Med Inhibiteurs de l'inactivation de neuropeptides endogenes notamment la cholecystokinine, leurs procedes de preparation leur utilisation comme medicaments et procede de criblage de medicaments
CN1933847A (zh) * 2004-01-16 2007-03-21 密歇根大学董事会 Smac肽模拟物及其应用
CA2573644A1 (en) * 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
CN101094833A (zh) * 2004-07-12 2007-12-26 伊邓药品公司 四肽类似物
NZ590550A (en) 2008-08-02 2013-05-31 Genentech Inc Inhibitors of Apoptosis (IAP) for treating cancer

Also Published As

Publication number Publication date
WO2014056755A1 (en) 2014-04-17
MX2015004465A (es) 2015-07-14
HK1211025A1 (zh) 2016-05-13
JP2015534567A (ja) 2015-12-03
US9403768B2 (en) 2016-08-02
KR20150065718A (ko) 2015-06-15
EP2906535B1 (en) 2018-08-08
CN104736519A (zh) 2015-06-24
CA2884708A1 (en) 2014-04-17
EP2906535A1 (en) 2015-08-19
JP6333825B2 (ja) 2018-05-30
CN104736519B (zh) 2018-12-04
US20150246882A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
JP2015537020A5 (enExample)
RU2015113959A (ru) Индолины
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2013510120A5 (enExample)
JP2014511892A5 (enExample)
RU2015118647A (ru) Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr
JP2017528498A5 (enExample)
JP2015510886A5 (enExample)
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
JP2009504763A5 (enExample)
JP2014518882A5 (enExample)
JP2018524298A5 (enExample)
JP2014511891A5 (enExample)
JP2017528467A5 (enExample)
RU2015107803A (ru) Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания
TR201802944T4 (tr) İlaç olarak azai̇ndazol veya di̇azai̇ndazol türünün türevleri̇
JP2015505296A5 (enExample)
RU2013140169A (ru) Противоопухолевое терапевтическое средство
EA201201031A1 (ru) Ингибиторы вируса гепатита с
RU2014107484A (ru) ПРИМЕНЕНИЕ СОЕДИНЕНИЙ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ПИРИМИДИН-5(1H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ LP-PLA2
RU2016131189A (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНДУКТОРОВ ЧЕЛОВЕЧЕСКОГО ИНТЕРФЕРОНА
JP2018502101A5 (enExample)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
RU2014131370A (ru) Терапевтические соединения, содержащие бор

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20171017